Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma - Bristol-Myers Squibb (NYSE:BMY)
Published on March 20, 2026.
Bristol-Myers Squibb (BMY) has received approval for Opdivo Plus Chemo for Untreated Hodgkin Lymphoma. The company's shares have fallen 1.33% since the announcement of the drug's approval. The study, CA209-8UT, demonstrated the effectiveness of nivolumab in combination with AVD in reducing disease progression-free survival (Possible), with a hazard ratio of 0.42.
Related Articles
Autism resource fair offers support for adults, families in Clark County
A resource fair for adults with autism will be held at Las Vegas City Hall on March 21, following a challenging transition for families.
Arizona prison system appeals order on inmate health care takeover
The Arizona prison system appeals a federal judge’s order placing prison health care under control, arguing it violates prisoners' rights and violates constitutional protections.
Federal judge sides with Washington in case over transgender youth health care
A federal judge will grant summary judgment to Washington state and 20 other states, blocking the Trump administration’s attempt to limit transgender youth care.